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ABSTRACT 
 
AKSHAY ASWATHA KUMARSWAMY: In Vivo Assessment of Osseous Wound 
Healing using Bone Putty in the Surgical Management of Tooth Extractions. 
 
Purpose: The objective of this pilot study was to evaluate the healing responses of a 
anesthetic bone putty in tooth extraction sockets of a canine model.  
Materials and Methods: In five beagle dogs the right mandibular premolars were 
extracted. The extraction sockets were grafted with one of the four treatment arms: 1) 
bone putty alone, 2) bone putty mixed with xenograft particulate bone (3:1), 3) xenograft 
sandwiched between bone putty and 4) xenograft covered with a collagen sponge. After 6 
weeks, the healing extraction sockets were evaluated by microCT and histological 
analysis.  
Results: All sockets healed without complications. By microCT analysis, sockets grafted 
demonstrated comparable radiographic evidence of bone healing compared to control 
sockets. Histologically, a minimal inflammatory infiltrate was present in all the sockets. 
Conclusions: Our pre-clinical results indicate that this bone putty is a safe, biocompatible 
device that may be useful in the post-operative management of tooth extractions.
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INTRODUCTION 
Extraction is the end of the road for a tooth. Alveolar bone resorption often occurs after a 
tooth extraction (1). The bones of the maxilla and mandible, as well as other bones carrying 
mechanical loads, adapt their strength to the applied load. Under such stress, the bone 
undergoes continuous remodeling and maintains its mechanical competence (2). A lack of 
such stress, one of them being in an extraction site, is often attributed to play a part in 
alveolar bone resorption (3). Other factors that play a role in alveolar bone resorption are 
related to metabolic (nutrition, hormonal and cellular activity), anatomic (size, shape and 
density of alveolar ridges) and prosthetic factors (4). Several studies have reported anywhere 
between 40-60% of extraction socket resorption within the first 3 years (5, 6). Mandibular 
sites have been observed to resorb four times faster than maxillary extraction sites (7). The 
advent of dental implants and their optimal placement necessitates preserving extraction 
sockets with bone grafts in a delayed implant placement scenario to maintain a healthy bone-
implant interface over a long period of time. The goal of socket preservation is to increase 
bone volume thereby promoting osseointegration and improving implant stability (8). 
Autografts, allograft, xenografts and non-osseous material like hydroxylapatite and bone 
ceramics are some of the wide range of bone grafting materials used in extraction sockets and 
periodontal defects (9). A better understanding of bone physiology and biomechanics has 
shown that bone grafts serve 3 primary functions of osteoinduction, osteoconduction and 
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osteogenesis. These will be defined and discussed further in a section ahead. Bone 
morphogenetic proteins and other biomimetic agents are being used to grow or augment bone 
in deficient sites (10). In general, the majority of these grafting solutions are available in the 
form of particulate bone chips, gels or liquids. The purpose of this review is to provide an 
overview of the extraction defect biology and the different materials used in preserving 
and/or augmenting this site in preparation for a predictable restoration of the edentulous site. 
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BIOLOGY OF THE HEALING EXTRACTION SOCKET 
The tooth extraction socket is a unique bony wound due to the presence of residual 
periodontal ligaments
 
unlike other bony wounds found in the human body (11). A blood clot 
is formed immediately after a tooth is extracted containing neutrophilic granulocytes and a 
network of cross-linked fibrin fibers along with plasma fibronectin, vitronectin and 
thrombospondin (12). This clot is also a reservoir of growth factors and cytokines that are 
released by the degranulation of activated platelets and serving as a provisional matrix for 
cell migration. These growth factors may in fact provide the start signals for wound repair 
and bone growth.(13) Indeed, the early healing events following tooth extraction, studied 
histologically in man, noted that bone formation begins as early as 10 days after extraction 
(11). Numerous studies
 
have shown that the infilling of the socket may be due to one or many 
of the different mesenchymal cells present in the extraction socket. These cells originate from 
the residual periodontal ligament, periosteum, bone marrow, or blood vessel-associated 
pericytes (14-16) where they group together, usually near or around blood vessels, and 
differentiate into osteogenic cells which deposit bone matrix, constitutively. The fibrin mesh 
helps form the scaffold in the extraction socket and helps organize aggregates of bony matrix 
called bone spicules. Separately, mesenchymal cells differentiate into osteoblasts and form 
the bone matrix, the osteoid, while expressing proteins namely osteonectin, osteopontin and 
osteocalcin (17). Osteoblasts line up along the surface of the spicule and continue to secrete 
osteoid resulting in the increases in size of the spicule. As the spicules continue to 
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grow, they fuse with adjacent spicules resulting in the formation of trabeculae. When 
osteoblasts become trapped in their own matrix, they differentiate into osteocytes. 
Osteoblasts continue to line up on the surface which increases the size. As growth continues, 
trabeculae become interconnected and woven bone is thus formed. The term primary 
spongiosa is often used to refer to the initial trabecular network. Thereafter, the periosteum is 
formed along the trabeculae by differentiating mesenchymal cells. The primary center of 
ossification is the area where bone growth occurs between the periosteum and the bone. 
Osteogenic cells that originate from the periosteum increase appositional growth and a bone 
collar is formed. The bone collar is eventually mineralized and lamellar bone is formed (11), 
(18). 
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RATIONALE FOR SITE PRESERVATION 
The need for alveolar ridge preservation is based on the observation that bone loss in a socket 
after tooth extraction is unavoidable and unpredictable (1). A study by Nevins demonstrated 
that sites without bone grafting had ˃20% loss of the buccal plate (19).  This can result in a 
significant bony defect and inadequate bone volume for implant placement. As discussed 
above, bone healing and subsequent new bone formation takes place mainly through 
osteoinduction, osteoconduction and osteogenesis. Bone grafts tend to possess one or more of 
these properties. Osteogenic cells may be transplanted into the recipient graft in autogenous 
bone or bone marrow. It is important to note that only freshly harvested autogenous bone 
grafts or bone marrow aspirates contain these cells (20).  
      Osteoconductivity is the ability of the material to act as passive scaffolding supporting 
new bone formation while facilitating ingrowth of capillaries and bone. A number of inert 
materials such as ceramic grafts have this property while allogenic materials are capable of 
undergoing creeping substitution (20). In contrast, osteoinduction is defined as the presence 
of differentiating factors within graft materials that facilitate the recruitment and 
differentiation of mesenchymal stem cells and specifically induce their formation into 
osteoblasts and subsequent new bone formation. The family of bone morphogenic proteins 
(BMP) is the prototypical stimuli. Other factors that contribute to this process include 
transforming growth factors (TGF-β), insulin-like growth factors (IGFs), fibroblast growth
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factors (FGFs), endothelial growth factors (EGFs) and platelet derived growth factors 
(PDGFs) (20).  
      A second important property of grafting materials is the ability to preserve the space 
required for new bone formation while helping exclude unwanted cells from the wound thus 
promoting the formation of new bone (21-23). Araujo and Lindhe studied the dimensional 
alterations of the alveolar ridge and the process of bone modeling and remodeling after tooth 
extraction in dogs over 8 weeks. The 3
rd
 and 4
th
 premolars of these dogs were hemisected and 
only the distal roots were extracted. The distal portion of the teeth was closed with the 
mobilized gingival tissue. Histologically, there was marked osteoclastic activity in the crestal 
portion of the buccal and lingual walls. Significantly, the buccal walls showed more 
resorption compared to lingual walls. The reduction in height was accompanied by varying 
degrees of horizontal bone loss as a result of osteoclastic activity along the buccal and lingual 
walls of the socket. The resorption of the buccal/lingual walls of the extraction site occurred 
in two overlapping phases. During phase 1, the bundle bone was resorbed and replaced with 
woven bone. Since the crest of the buccal bone wall was comprised solely of bundle bone, 
this modeling resulted in substantial vertical reduction of the buccal crest. Phase 2 included 
resorption that occurred from the outer surfaces of both bone walls (24). Several studies have 
confirmed this aspect of bone resorption in extraction sites. Lekovic and colleagues observed 
extraction sockets treated with and without absorbable barrier membranes. At 6 months, 
significantly less crestal bone loss (-0.38mm vs. -1.50 mm), more internal socket fill (-5.81 
mm vs. -3.94 mm), and less horizontal ridge resorption (-1.31 mm vs. -4.56 mm) were found 
in the membrane group than in the control group (25). Barone and co-workers used xenograft 
particulate bone to fill extraction sockets which they compared to ungrafted extractions 
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alone. Significantly greater horizontal resorption was observed at ungrafted extraction sites 
(4.3+/-0.8 mm) compared to grafted, ridge preserved sites (2.5+/-1.2 mm). The ridge height 
reduction at the buccal side was 3.6+/-1.5 mm for the extraction-alone group, whereas it was 
0.7+/-1.4 mm for the ridge-preservation group. Moreover, the vertical change at the lingual 
sites was 0.4 mm in the ridge-preservation group and 3 mm in the extraction-alone group 
(26). Biopsy cores harvested from the test and control sites revealed a significantly higher 
number of connective tissue in the ungrafted sites.  
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AUTOGENOUS GRAFTS 
Autogenous grafts are considered to be the gold standard for bone grafting procedures due to 
its osteogenic, osteoinductive, and osteoconductive properties (10). In addition, they do not 
present a risk of disease transmission as the donor and recipient site are obtained from the 
same patient (27, 28). Cancellous bone has a higher percentage of cells and as a result has 
more osteogenic potential. Several clinical case studies have highlighted the use of intra-oral 
sites such as the chin and the ramus as potential harvesting areas to augment ridge 
deficiencies reporting a considerable degree of  success with minimal to no complications 
(29-32). Palatal and mandibular tori have also been used to augment localized defects during 
implant site augmentation (33, 34). The potential complications encountered with such 
procedures are V3 paresthesia, insufficient cortical bone volume, disfiguration of the chin, 
infection and affecting adjacent tooth vitality (31, 35, 36). Extra-oral autogenous bone is 
available in larger quantities from iliac crest, rib, calvaria and tibia. The main advantage of 
autogenous bone is that it maintains bone structures such as minerals, collagen and viable 
osteoblasts (10). The main disadvantage is the requirement for a second surgical procedure 
and associated risks of pain, donor site morbidity and infection (1).
 
Donor site morbidity is 
not warranted for such a small defect (viz. an extraction site) when allografts have shown to 
be equally successful (9). There are essentially two forms of non-vascularized free 
autogenous bone grafts: cortical and cancellous. Cancellous grafts re-vascularize more 
rapidly and completely when compared to cortical grafts whereas cortical grafts are better 
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able to withstand mechanical forces (11). Further, autologous grafts have been successfully 
used alone or in combination with allografts and xenografts in socket preservation techniques 
in delayed as well as immediate implant placement (37, 38).  
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ALLOGRAFTS 
Allografts are bone grafts derived from the same species. They are commercially available in 
three forms: fresh frozen, freeze-dried bone allograft (FDBA) and demineralized freeze-dried 
bone allograft (DFDBA). FDBA is osteoconductive and osteoinductive and as the name 
implies, it is sterilized then freeze dried. Histological sections containing FDBA have shown 
osteoid forming bone spicules with osteoblasts observed at the rim of the osteoid deposits 
(39). DFDBA contains BMP‟s embedded in the matrix which aid in inducing bone 
formation. These BMP‟s are exposed during the demineralization process by osteoclasts (10). 
To date, 13 BMP proteins have been identified (BMP1-BMP13). Since BMPs are thought to 
possess osteoinductive and conductive properties, DFDBA is classified as such (40). A 
histological study in humans reported the presence of DFDBA particles at a significant 
distance from areas of bone formation and consisted of scarce connective tissue collagen 
fibers and empty osteocytic lacunae. This can be attributed to the presence of BMPs which 
may have induced bone formation (41).  
      Newer methods have recently been employed for the delivery of allograft materials. 
Carriers include collagen and/or selected polymers which contain the allograft material in a 
gel, putty or sponge-like consistency (40). Their potential uses include the treatment of 
periodontal bony defects, extraction sockets, ridge augmentations, cysts and bony defects of 
the jaw (40, 42). The main disadvantage of allografts is patient rejection due to religious 
beliefs or possible disease transmission. However, allografts undergo rigorous screening,
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selection and testing of donors to ensure they are free of any communicable diseases and as 
such are considered safe for use by the American Association of Tissue Banks (43).  
A recent systematic review published findings on the clinical effectiveness and predictability 
of allogeneic bone blocks for the correction of alveolar ridge deformities to support dental 
implant placement in humans.(44) A majority of the studies were observational studies in 
nature with no randomized clinical trials available in the literature to date. Although clinical 
evidence remained limited to case series and observations, these reports concluded that block 
allograft had a high rate of incorporation (˃90%) and implant survival (99-100%). An article 
by Holtzclaw (45) outlined the various steps starting from graft harvest to recipient surgery. 
As soon as the tissue is procured, a soft-tissue stripping is performed followed by a reduction 
in size to approximately 5mm for easier processing. Saline, acetone, ethanol or hydrogen 
peroxide are used to debride, clean and decontaminate followed by antimicrobial, 
antimycotic and antifungal treatment. Liquid nitrogen freezes the bone particles down to -80 
degrees C. The bone particles are then lyophilized with repetitive solvent washes to eliminate 
moisture content and reduce antigenicity. The particles undergo secondary size reduction 
approximately to about 250 to 750 micrometers. Thereafter, they are packaged in sterilized 
containers and undergo one final round of low-dose γ-radiation at low temperatures before 
being dispatched to the market.(45) 
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XENOGRAFTS 
Xenografts are bone tissues derived from a different species other than the recipient species 
(9). An experimental study in dog extraction sockets noted that the presence of a xenograft 
(Bio-Oss Collagen) failed to inhibit the processes of modeling and remodeling that took 
place in the socket walls following tooth extraction. In fact, it apparently promoted de novo 
hard tissue formation, particularly in the cortical region of the extraction site (46). Further 
studies done in beagle dogs by the same group reported that this xenograft material acted as 
an osteoconductive material, was present after 6 months, and counteracted marginal ridge 
contraction (46, 47).  
      A human histological study evaluated xenograft histomorphometrically, and calculated 
the mean percentage of bone, residual graft and connective tissue by area over a mean 
healing time of 6 months. The mean percentage bone-to-graft contact was also calculated. 
The mean percentage area of new bone formation was 26.9%, and the percentage of residual 
graft and connective tissue as 25.6% and 47.4%, respectively. The mean percentage contact 
length between bone and residual graft was 34%. After 6 months, the xenograft  still 
occupied 1/4
th
 of the area while another 1/4
th
 was occupied by new bone with connective 
tissue forming the remaining ½ (48). However, the resorption of bovine bone has been seen 
in animal studies (49) more so than in humans (50). Nevertheless, the maintenance of the 
physical socket dimension can be enhanced by the use of xenograft bone particulate material.   
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For patients, one of the main disadvantages of a xenograft may be patient anxiety due to their 
fear over Bovine Spongiform Encephalitis (BSE) or “mad cow disease”. BSE is transmitted 
by a protein known as a “prion”. To date, only 3 human cases of BSE have been reported in 
continental United States as a result of meat ingestion (51). Thus, the prion is contained 
within the bone‟s organic component so the risk of disease transmission is negligible as the 
organic components of bone are extracted during the processing and sterilization procedures 
(52). 
      Xenograft materials have been used in conjunction with bioactive peptides and have 
shown promising results in regenerating bone. A synthetically manufactured short chain 
amino acid peptide known as P-15 has been demonstrated to enhance bone activity. P-15 has 
been reported to attract and bind osteoblasts onto the bone grafting matrix. P-15 competes for 
attachment of collagen on cell surface sites and facilitates the physiological process similar to 
collagen by exchanging mechanical signals and promoting cell differentiation (53). P-15 
associated with a synthetic or anorganic bone matrix has also been reported to enhance the 
osteoinductive effect (54). 
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SYNTHETIC BONE SUBSTITUTES 
Synthetic bone substitutes are synthetically derived materials shown to be biocompatible, 
induce a minimal fibrotic reaction, and undergo remodeling and support new bone formation. 
Mechanically, these materials should have similar strength to that seen with 
cortical/cancellous bone (55). They should also be matched with a similar modulus of 
elasticity to that of bone (56). Synthetic materials that demonstrate some of these properties 
are composed of calcium and silicon. The disadvantages of these materials in the clinical 
settings include: low or unpredictable resorption, difficulty in handling (coral derived 
hydroxyapatite) and occasional inflammatory and foreign body reactions (56). Synthetic bone 
grafts used for site preservation to be discussed in this review include the ceramics such as 
calcium phosphates, calcium sulfates and composite polymers. Ceramics are inorganic 
crystalline materials that serve as synthetic scaffolds and are made from calcium phosphate 
currently in use in dentistry and in orthopedics (57). Tricalcium phosphate ceramic has a 
stoichiometry similar to bone precursors. They are not present naturally but have been shown 
to induce a biologic response similar to bone (58). Discussed further are a few of the 
synthetic bone substitutes used in clinical dentistry. 
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Calcium Phosphate and Derivatives 
Hydroxyapatite (HA) is a calcium phosphate derived bioactive material present in human 
bone and teeth (57). It can be extracted and obtained from natural sources such as bovine 
bone or coral. Coral porosity is an important property in its role as a graft material. The 
porosity size has been reported to be directly related to its rate of bone formation and 
resorption. The smaller the porosity, the greater its density and compressive strength and 
corals of higher porosity facilitate larger ion exchange thus promoting faster bone turnover 
(59). Corals are sintered at high temperatures which eliminate organic material including 
proteins thus preventing graft v/s host disease in patients. New bone is formed around the 
particulates of hydroxyapatite in stages. That is, by formation of fibrous tissue around the 
chips of HA and later forming woven bone. HA is noted histologically after new bone has 
been formed (60) and is generally osteoconductive although a few studies have suggested 
that it has osteoinductive properties (61-63). Hydroxyapatite has also been used as coating on 
dental implants to enhance their osseointegration potential. Direct bone attachment has been 
observed on plasma-sprayed HA-coated titanium alloy surface, while fibrous tissue was 
encapsulated on the uncoated surface.(64) The disadvantages of HA is the tendency for 
migration of the granules, the lack of complete resorptive process of the particles (65) and its 
bacterial susceptibility.(66)      
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Another derivate widely used in clinical dentistry is β-tricalcium phosphate. The first dental 
application was reported by Nery et al. in the 1970‟s using a synthetic porous material 
obtained by sintering a „tricalcium phosphate reagent‟ that was originally described  as 
“tricalcium phosphate” or “TCP” but later demonstrated to consist of a mixture of HA and 
TCP (67). Attachment as well as phagocytosis of tricalcium phosphate has been 
demonstrated in-vitro (64, 68)(64, 64, 68, 68, 69). TCP enhances attachment, proliferation, 
and differentiation of osteoblasts and expression of collagen, proteoglycans, osteopontin, 
osteocalcin and bone sialoprotein (70, 71). This supports the findings that TCP is an 
osteoconductive material (70) although it has been known classified as an osteoconductive 
material (72, 73). Since this osteoinductive property was observed in some calcium 
phosphate materials but not in others of similar composition, these materials were described 
to have „intrinsic‟ osteoinductivity. This inductive phenomenon for some calcium phosphate 
(CaP) materials was attributed to the topography, geometry, composition, macropore size, 
and percent porosity of the CaP. Such geometry was believed to allow entrapment and 
concentration of circulating bone growth factors (BMPs) and osteoprogenitor cells imparting 
osteoinductive properties to the CaP materials. An alternative method by which CaP can 
induce bone is by using it as a carrier. This is called “Engineered Osteoinductivity” i.e. the 
material is combined with growth factors which induce bone formation (67). This has been 
used in the field of periodontal regeneration in combination with collagen peptides and 
platelet derived growth factors (PDGF) (54, 74). However, one disadvantage for its use in 
extraction defects may be the high cost of PDGF. 
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Bio-Glass 
Bio-active glasses (BG) are silico-phosphate chains that are used in glass ionomer cements. It 
is considered to be highly biocompatible and exhibit bone bonding, a phenomenon also 
observed with other bioactive ceramics. This process is a result of the surface reactive silica, 
calcium, and phosphate groups that are characteristic of these materials. Silica is believed to 
play a critical role in bioactivity. These materials have the ability to chemically bond with 
bone and are proposed to function as small bone regenerative chambers (75). Although BG is 
generally used as a space-maintainer, their granular nature decreases their reliability. BG has 
been used for ridge augmentation for future dental implant placement (76-78). A histological 
and clinical study reported a clinical success rate of 96.8% with implants placed in BG 
preserved sites. A human histological study demonstrated that connective tissue was 
observed in the absence of an inflammatory response while increasing evidence of bone 
formation was seen in direct relation to the bioactive glass material after 6 months (79). 
However, there are no systematic reviews available on the use of BG and it is possible that 
biocompatibility and bone bonding ability could be enhanced if used as carrier materials for 
growth factors (80). 
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Calcium Sulfate 
Plaster of Paris or the β-hemihydrate form of calcium sulfate (CS) is one of the first materials 
investigated as a bone graft substitute. It has been extensively used in orthopedic surgery due 
to its inert, osteoconductive, rapid setting, resorbing and biocompatible properties (81). CS is 
soluble in vivo and acts as a source of calcium for mineral formation. It can be chemically 
synthesized or naturally obtained from mined gypsum (82). A few studies have used medical 
grade calcium sulfate for extraction site ridge preservation. Clinical and histological findings 
have revealed formation of trabecular bone with woven and lamellar arrangements (83-85). 
Dental implants placed in sites previously preserved with calcium sulfate have shown similar 
radiographic results to those placed in hydroxyapatite and porcine derived bone grafts (86). 
However, the main drawbacks are its mechanical strength which fails to provide adequate 
long term support to the defect site (87). Further, Plaster of Paris fails to form a chemical 
bond with bone tissue at the early stages due to its poor bioactivity and has a rapid rate of 
resorption which negatively affects bone regeneration (88). 
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OSTEOACTIVE AGENTS 
Osteoactive agents are materials which possess the ability to stimulate deposition of bone. 
They can be classified as osteoinducers, osteopromoters and bioactive peptides. The 
compounds in the first two categories are growth factors whose function is to regulate normal 
physiological processes and biological activities such as receptor signaling, DNA synthesis 
and cell proliferation (89). Growth factors are chemotactic, mitogenic and morphogenic in 
nature. Urist and co-workers demonstrated that demineralized bone matrix had low-
molecular weight proteins which induced bone induction, today known as BMP‟s (90). Since 
then, significant progress has been made in this field and has now included the 
commercially-availability of platelet derived growth factors, enamel matrix proteins and 
bioactive polypeptides. 
      Platelets contain a number of different growth factors which are released into the tissue 
after injury. These include transforming growth factor (TGF-β), platelet derived growth 
factor (PDGF), insulin-like growth factor (IGF), and fibroblast growth factor (FGF) which 
act as differential factors on hard and soft tissues (91). Commercially-available PDGF-B 
(GEM-21, Osteohealth, Shirley, NY) is packaged in a 0.3 mg/ml concentration in 
combination with β-TCP and has shown to result in excellent bone quality and quantity for 
future implant placement (92).  Platelet rich plasma (PRP) is a second potential source of 
concentrated platelets currently in use for bone regeneration. The processes for PRP 
preparation involves the collection of whole blood (with the anticoagulant citrate dextrose) 
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that undergoes two stages of centrifugation designed to separate PRP from low-platelet 
plasma and red blood cells.
 
Platelets are activated by mixing with a solution of calcium 
chloride thrombin, which activates the clotting cascade mechanism. The entire process, 
starting from its activation to secretion of factors, is completed in 10–15 minutes (93). A 
randomized clinical trial tested PRP against a control group composed of iliac crest grafts in 
sinus augmentation procedures. This investigation could not elicit any appreciable clinical 
advantage with the use of PRP (94). However, a meta-analysis by Bae and co-workers 
demonstrated that bone regeneration was higher in sites treated with PRP compared to other 
sites. In terms of implant stability, there were no significant differences between the test and 
control groups. They concluded that there was sufficient evidence to support the use of PRP 
(95). A systematic review also reported that PRP improved the handling characteristics of 
particulate bone graft but had very limited positive effects on bone healing (96). A 
disadvantage of using PP is the appreciable start-up costs the centrifuge and the time 
involved in preparing the PRP. 
      Enamel matrix proteins (EMP) have shown potential in the regeneration of lost 
periodontal attachment. This is achieved due to the effect of these proteins in the formation 
of acellular cementum, a key tissue in the development of a functional periodontium (97). 
However, its use as in ridge augmentation procedures is minimal due to the lack or need for 
acellular cementum in such sites. 
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BARRIER MEMBRANES 
Membranes are used in ridge preservation and guided-tissue regeneration (GTR) procedures 
and function as barriers to exclude rapidly-proliferating, non-bone inducing cells. A 
landmark study by Bowers demonstrated that cells that reach the wound site first tend to 
form or initiate its lineage (98-100). Membranes aid in excluding epithelial cells from the 
extraction site so that the osteoblasts are given the opportunity to reach the wound site first 
and form new bone. After tooth extraction they are commonly used (in combination with 
bone graft materials) in guided bone regeneration procedures in cases where the buccal plate 
of bone is thin or completely lost (101). These membranes are available in resorbable and 
non-resorbable forms. The non-resorbable membranes are primarily made of expanded poly-
tetra fluoro-ethylene (e-PTFA) and are often reinforced with titanium to enhance pliability 
and space maintaining properties. However, a second surgery is needed to retrieve these 
membranes from within the surgical area. The resorbable barrier membranes are made up of 
Type I and III bovine or porcine collagen and resorb in 18-24 weeks by enzymatic 
degradation (102). Some are chemically treated to prolong their barrier function. Further, 
acellular dermal allografts, bovine and human pericardium has been shown to be effective as 
barrier membranes (103, 104)(105, 106). Lekovic et al. observed the clinical effectiveness of 
barrier membranes in preserving alveolar ridges after tooth extraction. Results showed that 
membrane-covered sites presented with significantly less ridge atrophy than control sites 
(107). Selection of barrier membrane depends on resorbability, defect size and morphology, 
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operator preference and patient acceptance (108). Difficulties associated with barrier 
membrane use during socket augmentation include the potential reduction of keratinized 
gingival, alterations of gingival contours, and migration of the mucogingival junction, as a 
result of coronal displacement of the flap in an attempt to achieve soft tissue closure over the 
membrane (109). 
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SUMMARY 
Bone is a dynamic tissue due to its constant ability to form and resorb. Its unpredictable 
nature can be managed with the use of bone grafts. Numerous surgical techniques and 
materials have been documented in the literature to augment or preserve bone. The ability of 
natural or synthetic bone grafts to help form bone largely depends on the innate properties of 
the graft materials and the host response. These properties include chemical composition, 
morphology, porosity and particle size. The clinical choice of bone graft materials is 
dependent on operator and patient factors. Each of the materials presented in this review have 
demonstrated success in ridge preservation techniques. This is largely due to these materials‟ 
biologic or physical resemblance to natural bone. Osteoactive or bio-modifying agents have 
ushered in a new era of therapy in clinical dentistry.  These agents elicit cell and tissue-
specific responses that signal the initiation of new bone formation. Further research is needed 
to determine the application of these bio-modifiers in preserving and augmenting the bone 
present in the human extraction socket. Thus, while autologous grafts are the gold standard, 
the requirement for a second surgical site and the availability and predictability of 
commercially available materials has questioned the need for autogenous grafts (110). 
Advances in material science, cellular/molecular biology, and surgical techniques will 
continue to provide therapeutically meaningful outcomes in bone regeneration procedures. 
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IN VIVO ASSESSMENT OF OSSEOUS WOUND HEALING USING BONE PUTTY 
IN THE SURGICAL MANAGEMENT OF TOOTH EXTRACTIONS 
 
INTRODUCTION TO CLINICAL STUDY 
The extraction of teeth is a common procedure performed in clinical dentistry to address 
severely decayed, periodontally-involved, non-restorable or impacted teeth. A majority of 
these extractions are performed using lidocaine as the local anesthetic agent (111). 
Unfortunately, exodontia can be associated with significant post-operative pain and bleeding 
especially in patients on anti-coagulant therapy (112). 
 
To address post-operative discomfort, 
analgesics are often prescribed. These analgesics tend to have 4-6 hours duration of action 
when taken orally, and may require multiple dosing of up to 4-6 tablets daily (113). 
However, this can be associated with unwanted side-effects of the gastrointestinal, 
cardiovascular, and renal systems (114). Prolonging the duration of analgesia without 
increasing local or systemic levels of these analgesics becomes a desirable goal in clinical 
practice. Local drug delivery systems have been developed in dentistry but very few 
addressed delivery of anesthetic or analgesic agents (116-120). In fact, an online search of 
the MEDLINE database using key words „dental‟, „local‟, „delivery‟, „anesthetic‟ and 
„analgesic‟ identified only 1 study (115) thus highlighting the need for further study. Xybrex 
bone putty is an implantable, hand-moldable (with a consistency similar to modeling clay), 
absorbable delivery system that provides the controlled release of lidocaine and is based on a 
Food and Drug Administration-approved absorbable bone hemostat. Its constituents are a 
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bioresorbable mixture of calcium stearate (a wax-like tamponade), 16% (w/w) lidocaine, 
liquid vitamin E (for handling properties) and alkylene oxide copolymer (a dispersing agent). 
It has been previously shown to provide several days of functional sciatic nerve blockade in 
rats (116) and is currently being marketed to orthopedic surgeons for local pain management 
and bone hemostasis. It is possible that hemostatic bone putty containing a slow release 
anesthetic may be therapeutically beneficial in the management of simple and complicated 
exodontia. Further, a mixture of bone putty with particulate bone material may provide these 
same benefits  in addition to helping conserve the three dimensional architecture of the 
extraction socket in preparation for implant placement (9). The main objectives of this pilot, 
preclinical study are to assess the safety profile, biocompatibility and healing response of oral 
tissues to this bone putty in a dog tooth extraction model. 
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MATERIALS AND METHODS 
Surgical Procedure 
The animal experimental protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of North Carolina at Chapel Hill. Five female beagle 
dogs approximately a year old and weighing approximately 25 pounds were used in this 
study. All dogs had a full set of erupted permanent teeth with minimal plaque around the 
necks of the teeth. The dog extraction site model was used for this study (117). The animals 
were anesthetized intravenously with 4-6mg/kg sodium pentothal. Once under anesthesia, the 
animals were intubated to maintain a patent airway.  The level of anesthesia was maintained 
and monitored with the help of a blood pressure cuff and pulse oximeter by a veterinarian. 
Blood was drawn from each of the animals for a pre-operative blood chemistry panel 
inclusive of liver function tests. Thereafter, 2% lidocaine was infiltrated into the buccal and 
lingual tissues of the right side of the mandibular arch. The mandibular right 1
st
, 2
nd
, 3
rd
 and 
4
th
 premolars were hemisected with a thin fissure bur under copious irrigation and 
atraumatically extracted with elevators and forceps. The extraction sockets were thoroughly 
debrided and grafted with one of the four treatment arms: a) bone putty only [BP], b) bovine 
xenograft particulate (BioOss, Osteohealth Inc., Shirley, NY) and collagen plug (CollaPlug-
Zimmer Dental, Carlsbad, CA), [X] c) xenograft particles sandwiched between layers of 
putty placed in the coronal and apical aspect [XBX], d) A 3:1 mixture by weight of 
 
putty and 
xenograft particle respectively [XB3].
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The xenograft/collagen plug socket served as the control in each animal. The extraction 
sockets were then sutured and stabilized with 4-0 chromic gut suture. 
Post-Operative Care and Euthanasia 
The dogs were maintained on a mush diet for the entire duration of the study. Post 
operatively, Ibuprofen 400mg and Amoxicillin 500mg were given orally, three times a day 
for 3 and 7 days respectively. Visual observations of soft tissue healing were made every two 
days for 6 weeks. After 6 weeks, a second round of blood was drawn for complete blood and 
electrolyte count. Thereafter, the animals were euthanized with an overdose of pentobarbital 
(120mg/kg IV) through the carotid arteries. A mixture of 5% glutaraldehyde and 4% 
formaldehyde were infused and mandibles dissected en-bloc. The right side was resected 
from the canine to the 1
st
 molar with a high speed disc bur and placed in 4% 
paraformaldehyde. 
Blood Chemistry Panel 
Pre-surgical and 6 week blood samples were assayed for complete blood chemistry panel 
including liver function tests which included albumin, alanine transaminase (SGPT) and 
aspartate transaminase (SGOT). This was done as lidocaine is metabolized mainly in the liver 
and thus helps determine any toxicity. 
Radiographic Analysis 
Conventional radiographs were taken immediately after resection (Faxitron X-ray 
Lincolnshire, IL, USA) to qualitatively examine for the presence of residual material and 
general appearance of the socket. This was followed by a micro computed tomography (μCT) 
scan (SCANCO Medical μCT 40, Brüttisellen, Switzerland) to acquire basis images from 
which axial slices and cross-sectional images were generated. Each slice was 0.07mm in the 
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bucco-lingual direction with 1144 slices obtained per sample. The entire section was scanned 
with a resolution of 1024x1024 pixels. Each slice was then examined at a 2x magnification 
and the sockets were marked as a region of interest. All material present within the region of 
interest in each socket was included and determined to be the „Total Volume‟. After 
scanning, the 3-D data sets were segmented by using individual global thresholds, above 
which all pixels are considered bone, and below which all pixels are considered non-bone. 
The threshold of each data set was determined using an adaptive method, where the gray 
level data set is segmented at different levels. The threshold, where the volume fraction 
changes the least, i.e. the steepest gradient of gray levels, was chosen as the threshold for the 
data set (Scanco Medical AG, 1997). These µCT images were then analyzed in 3D using 
μCT analysis software (SCANCO Medical, Brüttisellen, Switzerland) according to 
manufacturer‟s instructions. Ratio of Bone Volume to Total Volume of extraction socket and 
Mean Bone Density measurements (as measured with mg HA/mm
3
) were obtained. 
Histological Analysis 
Each specimen was fixed in 10% buffered formalin after harvesting.  The specimens were 
then decalcified using an immunohistochemistry-compatible demineralizing agent 
(ImmunoCal
™
- Decal Chemical Co., Tallman, NY).  After demineralization, each specimen 
was processed for routing histology and embedded in paraffin to make tissue blocks.  
Sections were cut in the bucco–lingual dimension. The sections were stained in 
Haematoxylin-Eosin and Gomori Trichrome staining.  Serial sections were observed under a 
light microscope (Olympus DX41, Center Valley, PA) Magnifications of 100x, 200x and 
400x was used to qualitatively assess each extraction socket/graft site. 
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Statistical Analysis 
A One-Way Analysis of Variance, Kruskal-Wallis Test and the post-hoc Dunn‟s multiple 
comparison tests were used to compare the animals with the different treatment groups as the 
variables (GraphPad Software Inc., La Jolla, CA). 
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RESULTS 
Handling Characteristics 
The BP material was moldable and could be shaped and compressed into the socket with 
finger pressure (Figure 1). Rapid and sustained hemostasis was obtained when applied into 
the extraction socket. The material tended to be somewhat sticky but was favorable when 
mixed with xenograft particulate.  
Safety Assessment 
All the animals tolerated the procedure well and did not display any signs such as raised body 
temperatures or any swelling on the face, indicative of infection, over the entire duration of 
the study. The 48 hour visual examinations of the extraction sockets over the duration of 6 
weeks revealed the normal stages of healing of extraction sockets. Initially the area was filled 
with a whitish granulation tissue. This slowly turned pinkish red, eventually resulting in 
epithelial closure over the extraction site. Rapid and complete soft tissue closure was noted 
over each of the extraction sockets in all the animals regardless of the treatment arm (Figure 
2). Comparison of pre- and post-operative clinical chemistries revealed normal mean levels 
of most of the blood chemistries and liver function tests. Table 1 and 2 displays the blood 
chemistry panel for 2 representative animals with the mean ranges of each test. No 
significant differences were noted for any of the clinical chemistries for all the animals. 
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Radiological Assessment 
Conventional 2D radiograph taken after 6 weeks revealed complete socket fill in all sockets 
of all the animals (Figure 3). Radiographic density was comparable amongst all the sites. 
µCT analysis was performed to determine the density of the materials. This is shown in 
Table 3. Significant differences can be noted between the materials with the bone putty 
having the lowest and the xenograft having the highest density. μCT analysis for the ratio of 
bone volume to total volume for each of the material and animals is shown in Table 4. The 
bone density measurements for the different treatment groups are shown in Table 5. The BP-
treated sites had a mean ratio of bone volume to total volume of 0.557 ± 0.05. In comparison, 
the X sites had a mean ratio of 0.5544 ± 0.05 while the treatment arms XBX and XB3 had 
mean ratios of 0.482 and 0.491 respectively with similar standard deviations of 0.114. The 
mean bone density for BP and X sites was 816 ± 12.7 mg HA/mm
3
 and 841.7 ± 20.97 mg 
HA/mm
3 
respectively. The XBX group had a mean density of 838.6 ± 3.91 mg HA/mm
3
 
while the XB3 group had a mean density of 822 ± 11.8 mg HA/mm
3
. There were no 
statistically significant differences between the different treatment arms for bone density. 
Overall there were no statistically significant differences between treatment groups when 
compared with a Dunn‟s multiple comparison tests at a p value ≤ 0.05 
Histological Assessment 
Serial sections were observed under a light microscope at multiple magnifications. The 
socket could be identified due to the difference in the depth of staining between the cortical 
bone and immature vital bone as well as the presence of the cement line lines and woven 
bone in the new bone and lamellar bone in the native mandible.  Each socket demonstrated 
some loss of buccal bone as in agreement with other animal studies (118). 
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      The sockets treated with BP contained appreciable amounts of vital bone. Voids could be 
observed which may have been previously filled with the bone putty material (Figure 4) but 
the material was likely lost during processing of the tissue. As expected, the sockets grafted 
with xenograft and collagen sponge [X] contained remnants of xenograft particles between 
the newly formed bone (Figure 5). The XBX and XB3 sites showed similar findings as the 
bone putty and xenograft sockets except for 1 animal that displayed evidence of a foreign 
body reaction with inflammatory cell infiltrate in one XBX site (Figure 6). That socket 
showed that there is no bone surrounding the xenograft particle (Figure 7). All other sockets 
appeared to display normal healing. 
       Gomori Trichrome staining was also used to distinguish new bone and osteoid from 
native lamellar bone. Osteons can be seen in Figure 8 representing the BP grafted sites 
stained blue indicating that the connective tissue present in the sockets was indeed bone 
matrix that is maturing in those areas. The areas of voids can also be observed as mentioned 
earlier. Figure 9 illustrates a xenograft site [X]. Bone particles (stained light blue) can be 
seen surrounded by osteoid and bone matrix. Areas which are stained with a pinkish hue are 
suggestive of more mature bone. 
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DISCUSSION 
The present study in animals evaluated the use of hemostatic and anesthetic bone putty 
following tooth extraction in different configurations and was compared to a xenograft and a 
collagen plug which is often used for extraction and site preservations procedures in human 
extraction sockets. The main goals of this study were to assess the material‟s safety profiles 
locally and systemically with the help of blood chemistry panel as well as to characterize the 
radiographic and histological response. Secondarily we sought to note its handling 
characteristics and hemostatic properties. Human clinical trials will assess the analgesic 
properties.  
      We noted that although the material was slightly sticky, this property appeared to help 
maintain it within the extraction sockets. We also noted immediate and sustained hemostasis 
(i.e. the bleeding from the socket did not last more than a few seconds) in sockets grafted 
with BP, XBX, or XB3. Anecdotally, the control socket demonstrated rapid hemostasis 
although it was slightly slower than sites grafted with the bone putty.   
Healing progressed normally and complete soft tissue closure was observed in the surgical 
site over the 6 week period without any untoward allergic or anaphylactic reactions. At 6 
weeks, µCT analysis all specimens failed to demonstrate statistically significant (p ≤ 0.05) 
differences in bone density suggesting that the bone putty did not interfere with bone 
metabolism compared to control sockets. Further, with the exception of 1 socket, the 
histological images containing the bone putty material did not show any untoward 
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inflammatory reaction after 6 weeks. A few voids were noted histologically in the BP-
containing sockets in the absence of an inflammatory infiltrate which may have been 
previously occupied by the material. This could be due to the decalcification and histological 
processing. Alternatively, the material could be well on its way to resorption within the 
socket. Indeed, in orthopedic surgical procedures, the BP is resorbed in approximately 4 
weeks time (personal communication, Orthocon, Inc., Colts Neck, NJ). In agreement with 
other studies, the X particles did not resorb completely over 6 weeks. It has been previously 
reported that xenograft particles could be observed after 6 months in dogs (47).  
As seen in Figure 10 the ratio of bone volume to total volume of the socket ranged around 
40%-60%. The high standard deviation was noted in XBX and XB3 grafted sites possibly 
due to varied bone formation in these sites. Further, the density of sockets grafted with BP 
was lower than those grafted with X (Figure 11). This is consistent with the fact that BP does 
not contain any mineralized particles. Conversely, xenograft is made of inorganic bovine 
bone and as expected, sockets grafted with X showed the highest density compared to 
sockets containing BP. In addition, it is possible that differences in bone formation and 
resorption rates may vary between animals.   
      The calcification of bone matrix increases bone density over time (119). Histologically, 
most of the sockets showed a minimal inflammatory infiltrate suggesting that all materials 
used were well tolerated by the animals. One socket in one animal showed evidence of a 
foreign body reaction with minimal formation of bone in one of the sockets (Figure 6, 7).  
Further studies should help clarify this finding. However, the material is FDA approved for 
use in orthopedic procedures and has been noted to demonstrate a minimal inflammatory 
reaction in other animal models (personal communication, Orthocon Inc., Colts Neck, NJ). 
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This finding could also be attributed to the fact that the uses in orthopedic medicine are under 
sterile conditions and the dogs were not in a gnotobiotic state so they may have had 
significant contamination form daily activities like eating and chewing. 
     Nevertheless, we noted bone formation in sockets grafted with BP and also noted that it 
did not interfere with bone formation when combined with X. 
The potential limitations of this study were: that the analgesic properties of the BP were not 
determined; the lack of randomization; small number of animals; the absence of dynamic 
histomorphometry; and the absence of untreated extraction sites (clot only)
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CONCLUSIONS 
Our pre-clinical pilot study indicates that bone putty, when used alone or in combination with 
xenograft bone particulate, did not induce adverse local, systemic or radiographic responses. 
With the exception of one socket, the histological assessment indicated that the bone putty 
tested did not interfere with the normal healing process in an extraction socket. Thus this 
bone putty appears to be a safe, bio-compatible product when used in extraction sockets. 
Further studies are required to confirm these findings as well as to assess its analgesic 
properties in extraction sockets.
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FIGURES AND TABLES 
Table 1.  Blood chemistry tests of two representative animals (before surgery). 
Test  Animal 1 Animal 2 Reference Range Units 
Total Protein 5.7 5.7 5.0-7.4 g/dL 
Albumin 3.6 3.4 2.7-4.4 g/dL 
Globulin 2.1 2.3 1.6-3.6 g/dL 
Cholesterol 143 221 92-324 mg/dL 
SGOT 30 21 15-66 U/L 
SGPT 33 74 12-118 U/L 
Alkaline Phosphatase 25 20 5-131 U/L 
GGT <5 <5 1-12 U/L 
Total Bilirubin 0.2 0.2 0.1-0.3 mg/dL 
Amylase 605 580 290-1125 U/L 
Urea Nitrogen 12 16 6-25 mg/dL 
Creatinine 0.5 0.7 0.5-1.6 mg/dL 
BUN/Creatinine ratio 24 23 4-27 Ratio 
Phosphorus 5.3 4.3 2.5-6.0 mg/dL 
Glucose 96 107 70-138 mg/dL 
Calcium 9.7 10.4 8.9-11.4 mg/dL 
Magnesium 1.4 1.6 1.5-2.5 mEq/L 
Sodium 145 146 139-154 mEq/L 
Potassium 4.2 4.6 3.6-5.5 mEq/L 
Triglycerides 21 26 29-291 mg/dL 
CPK 122 128 59-895 U/L 
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Table 2.  Blood chemistry tests of two representative animals (after surgery). 
Test  Animal 1 Animal 2 Reference Range Units 
Total Protein 5.6 5.6 5.0-7.4 g/dL 
Albumin 3.5 3.4 2.7-4.4 g/dL 
Globulin 2.1 2.2 1.6-3.6 g/dL 
Cholesterol 163 176 92-324 mg/dL 
SGOT 23 27 15-66 U/L 
SGPT 25 39 12-118 U/L 
Alkaline Phosphatase 27 24 5-131 U/L 
GGT <5 <5 1-12 U/L 
Total Bilirubin 0.1 0.1 0.1-0.3 mg/dL 
Amylase 635 694 290-1125 U/L 
Urea Nitrogen 12 15 6-25 mg/dL 
Creatinine 0.4 0.7 0.5-1.6 mg/dL 
BUN/Creatinine ratio 30 21 4-27 Ratio 
Phosphorus 4.0 3.8 2.5-6.0 mg/dL 
Glucose 94 104 70-138 mg/dL 
Calcium 9.0 10.3 8.9-11.4 mg/dL 
Magnesium 1.4 1.5 1.5-2.5 mEq/L 
Sodium 144 152 139-154 mEq/L 
Potassium 3.2 4.5 3.6-5.5 mEq/L 
Triglycerides 24 32 29-291 mg/dL 
CPK 103 166 59-895 U/L 
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Table 3. Density measurements of the materials (mg/mm
3
). 
Materials Density(mg/mm
3
) 
BP 387.66 
X 607.45 
XB3 435.93 
XBX 452.71 
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Table 4.  Summary statistics for Ratio of Bone Volume to Total Volume (p ≤0.05). 
 BP X XBX XB3 
Minimum 0.4795 0.4876 0.3118 0.3408 
25% Percentile 0.5112 0.5078 0.3832 0.3716 
Median 0.5565 0.5494 0.4705 0.5359 
75% Percentile 0.6050 0.6035 0.5874 0.5891 
Maximum 0.6115 0.6038 0.5968 0.6053 
Mean Ratio 0.5578 0.5544 0.4823 0.4914 
Std. Deviation 0.05220 0.05002 0.1143 0.1142 
Std. Error 0.02334 0.02237 0.05111 0.05108 
Lower 95% CI 0.4929 0.4923 0.3404 0.3496 
Upper 95% CI 0.6226 0.6165 0.6242 0.6333 
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Table 5.  Summary statistics for Bone Density Measurements (measured in mg HA/mm3) 
(p≤0.05). 
 BP X XBX XB3 
Minimum 800.9 816.9 833.8 809.2 
25% Percentile 802.3 823.0 835.1 810.3 
Median 822.2 843.5 837.6 824.8 
75% Percentile 826.6 859.4 842.6 832.2 
Maximum 827.6 872.7 842.7 837.8 
Mean 816.0 841.7 838.6 822.0 
Std. Deviation 12.70 20.97 3.911 11.80 
Std. Error 5.7 9.4 1.7 5.3 
Lower 95% CI 800.2 815.6 833.7 807.3 
Upper 95% CI 831.8 867.7 843.5 836.6 
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Figure 1.  Demonstration of the compressible characteristics of bone putty. 
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Figure 2.  Six week post-operative clinical view.  Occlusal view of the right mandibular ridge 
demonstrating complete closure of extraction sockets and lack of clinical signs of 
inflammation. 
 
  
44 
 
 
Figure 3.  Conventional radiograph taken at time of euthanasia (6 weeks post-op).  This 
figure represent an image from one of the animals.  Each of the sockets is represented by the 
configuration grafted. 
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Figure 4.  Photomicrograph of a socket treated with bone putty (BP).  Note the islands of 
bone tissue.  Hematoxylin and eosin stain.  Magnification – 100X. 
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Figure 5.  Photomicrograph of a Xenograft particle(a) surrounded by vital bone in a site 
grafted with xenograft.  Hematoxylin and eosin staining.  Magnification – 100X. 
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Figure 6.  Photomicrograph of XBX site in one animal.  Inflammatory cell infiltrate seen 
adjacent to the wall of the socket which is stained pink.  Gomori Trichrome staining.  
Magnification – 100X. 
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Figure 7.  Photomicrograph of a xenograft particle in a XBX filled socket in one animal.  
Note the minimal amount of bone forming cells around the xenograft particle.  Gomori 
Trichrome staining.  Magnification – 100X. 
 
B 
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Figure 8.  Photomicrograph of BP site with Gomori Trichrome staining.  Immature vital bone 
is stained blue while the pink hue is suggestive of an advanced stage in the maturation 
process.  Magnification – 100X. 
 
 
 
 
 
 
50 
 
 
Figure 9.  Photomicrograph of xenograft particles (light blue) surrounded by osseous tissue 
which is stained a darker shade of blue.  The pink staining indicates an advanced stage of 
maturation when compared to the dark blue stained tissue.  Gomori Trichrome staining.  
Magnification – 100X.  
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Figure 10.  A box plot showing the ratio of bone volume to total volume within the 
region of interest.  The X-axis shows the ratio while the Y-axis shows the different 
treatment arms. 
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Figure 11.  Box plot representing the density measurements in mg HA/mm3. 
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